AstraZeneca is delighted to be partnering with ELRIG as a sponsor of the 2014 Drug Discovery meeting.
At AstraZeneca we push the boundaries of science to deliver life changing medicines to the patients that need them. Great Science and open innovation is at the heart of our discovery strategy. Through both internal research and collaboration we aspire to access the best scientific minds to solve complex problems to deliver breakthrough science. At AstraZeneca we have an established track-record of Open Innovation having established relationships with, amongst others, the Medical Research Council, the US National Institute of Health and the UK Cancer Research Campaign. To enhance these initiatives, we have recently launched our new Open Innovation Portal , a single interface through which academic investigators can gain access to a range of AstraZeneca capabilities including compound sets for screening, and pre-clinical and clinical development compounds for hypothesis testing. Take a look and collaborate with AstraZeneca.
AstraZeneca is committed to UK science. In 2016 we will relocate UK large and small molecule discovery science to a new facility on the Cambridge BioMedical Campus . This world-leading centre will house scientists working in Discovery Science, Oncology Research, Drug Safety and Metabolism, Personalised Healthcare and other functions. We are already active in the Cambridge area and anticipate to have 200 scientists in place over the next 12 months. Access this link ( http://www.astrazenecacarees.com ) to learn more about our plans for Cambridge and the exciting opportunities to perform great science with us.
AstraZeneca has a long and successful association with ELRIG. The ELRIG Drug Discovery meeting is the premier networking and educational event for industrial, biotech and academic scientists interested in drug discovery in the UK. Through this event we look forward to establishing new relationships to continue to build the quality of UK science to create great medicines.